miglustat has been researched along with HIV Coinfection in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (66.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, YD; Chen, L; Huang, T; Jiang, M; Kong, XY; Li, BQ; Lu, J; Niu, B; Wei, ZJ; Zheng, MY | 1 |
| Burton, DR; Dwek, RA; Pollock, S; Zitzmann, N | 1 |
| Aspinall, RL; Collier, AC; Coombs, R; Fass, RJ; Fife, KH; Fischl, MA; Kremer, AB; Pottage, JC; Powderly, WG; Resnick, L | 1 |
| Fischl, M; Karim, A; Kessler, H; Merigan, T; Pottage, J; Powderly, W; Richman, D; Sherman, J; Smith, S; Tierney, M | 1 |
| Butters, TD; Dwek, RA; Fischer, PB; Karlsson, GB; Platt, FM | 1 |
| Dwek, RA; Fischer, PB; Karlsson, GB; Platt, FM | 1 |
2 trial(s) available for miglustat and HIV Coinfection
| Article | Year |
|---|---|
The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3.
Topics: 1-Deoxynojirimycin; Adult; Antiviral Agents; beta 2-Microglobulin; CD4-Positive T-Lymphocytes; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Hemoglobins; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Leukocyte Count; Male; Neutrophils; Paresthesia; RNA, Viral; Zidovudine | 1994 |
The tolerability and pharmacokinetics of N-butyl-deoxynojirimycin in patients with advanced HIV disease (ACTG 100). The AIDS Clinical Trials Group (ACTG) of the National Institute of Allergy and Infectious Diseases.
Topics: 1-Deoxynojirimycin; Adult; Animals; Antiviral Agents; Cataract; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Diarrhea; Female; Flatulence; Half-Life; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Lens, Crystalline; Leukopenia; Liver; Male; Neutropenia; Rats | 1995 |
4 other study(ies) available for miglustat and HIV Coinfection
| Article | Year |
|---|---|
Identifying chemicals with potential therapy of HIV based on protein-protein and protein-chemical interaction network.
Topics: 1-Deoxynojirimycin; Algorithms; Anti-HIV Agents; CCR5 Receptor Antagonists; Computer Simulation; Cyclohexanes; Databases, Chemical; Didanosine; Drug Design; Drug Discovery; HIV Infections; HIV-1; Host-Pathogen Interactions; Humans; Maraviroc; Models, Molecular; Protein Interaction Mapping; Protein Interaction Maps; Receptors, CCR5; Triazoles | 2013 |
N-Butyldeoxynojirimycin is a broadly effective anti-HIV therapy significantly enhanced by targeted liposome delivery.
Topics: 1-Deoxynojirimycin; Anti-HIV Agents; Cells, Cultured; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Resistance, Viral; HIV Infections; HIV-1; HIV-2; Humans; Leukocytes, Mononuclear; Liposomes; Virulence; Virus Replication | 2008 |
N-butyldeoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with changes in antibody recognition of the V1/V2 region of gp120.
Topics: 1-Deoxynojirimycin; Animals; Antiviral Agents; CHO Cells; Cricetinae; Epitopes; HIV Antibodies; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Protein Conformation; Virus Replication | 1996 |
N-butyldeoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with impaired gp120 shedding and gp41 exposure.
Topics: 1-Deoxynojirimycin; Animals; Antiviral Agents; CHO Cells; Cricetinae; HIV Envelope Protein gp120; HIV Envelope Protein gp41; HIV Infections; HIV-1; Humans; Virus Replication | 1996 |